GB8601915D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
GB8601915D0
GB8601915D0 GB868601915A GB8601915A GB8601915D0 GB 8601915 D0 GB8601915 D0 GB 8601915D0 GB 868601915 A GB868601915 A GB 868601915A GB 8601915 A GB8601915 A GB 8601915A GB 8601915 D0 GB8601915 D0 GB 8601915D0
Authority
GB
United Kingdom
Prior art keywords
treatment
conditions
physiologically acceptable
pharmaceutical compositions
essential fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB868601915A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Efamol Ltd
Original Assignee
Efamol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efamol Ltd filed Critical Efamol Ltd
Priority to GB868601915A priority Critical patent/GB8601915D0/en
Publication of GB8601915D0 publication Critical patent/GB8601915D0/en
Priority to AU67675/87A priority patent/AU593317B2/en
Priority to IE19487A priority patent/IE59606B1/en
Priority to ZA87560A priority patent/ZA87560B/en
Priority to DE8787300630T priority patent/DE3774449D1/en
Priority to ES198787300630T priority patent/ES2040242T3/en
Priority to EP87300630A priority patent/EP0234733B1/en
Priority to AT87300630T priority patent/ATE69378T1/en
Priority to JP62015904A priority patent/JPS62185018A/en
Priority to US07/007,109 priority patent/US4753964A/en
Priority to US07/147,208 priority patent/US4810497A/en
Priority to GR91401658T priority patent/GR3003120T3/en
Priority to SG114293A priority patent/SG114293G/en
Priority to HK1278/93A priority patent/HK127893A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

This invention relates to the treatment of presenile or senile dementia and in particular to the treatment of Alzheimer's disease. It is proposed that such conditions may be combatted or their effects alleviated by the administration of a physiologically acceptable lithium compound and/or of an essential fatty acid or a physiologically acceptable salt thereof and there is described herein the use of lithium compounds and/or essential fatty acids or salts thereof for the manufacture of therapeutic agents for combatting such conditions.
GB868601915A 1986-01-27 1986-01-27 Pharmaceutical compositions Pending GB8601915D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GB868601915A GB8601915D0 (en) 1986-01-27 1986-01-27 Pharmaceutical compositions
AU67675/87A AU593317B2 (en) 1986-01-27 1987-01-19 Pharmaceutical compositions
JP62015904A JPS62185018A (en) 1986-01-27 1987-01-26 Medicinal composition
EP87300630A EP0234733B1 (en) 1986-01-27 1987-01-26 Pharmaceutical compositions
ZA87560A ZA87560B (en) 1986-01-27 1987-01-26 Compound for the manufacture of a therapeutic agent
DE8787300630T DE3774449D1 (en) 1986-01-27 1987-01-26 PHARMACEUTICAL COMPOSITIONS.
ES198787300630T ES2040242T3 (en) 1986-01-27 1987-01-26 PHARMACEUTICAL COMPOSITIONS.
IE19487A IE59606B1 (en) 1986-01-27 1987-01-26 Pharmaceutical compositions
AT87300630T ATE69378T1 (en) 1986-01-27 1987-01-26 PHARMACEUTICAL COMPOSITIONS.
US07/007,109 US4753964A (en) 1986-01-27 1987-01-27 Pharmaceutical compositions of lithium compounds to treat presenile or senile dementia
US07/147,208 US4810497A (en) 1986-01-27 1988-01-22 Pharmaceutical compositions
GR91401658T GR3003120T3 (en) 1986-01-27 1991-11-14 Pharmaceutical compositions
SG114293A SG114293G (en) 1986-01-27 1993-10-18 Pharmaceutical compositions
HK1278/93A HK127893A (en) 1986-01-27 1993-11-18 Pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868601915A GB8601915D0 (en) 1986-01-27 1986-01-27 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GB8601915D0 true GB8601915D0 (en) 1986-03-05

Family

ID=10591997

Family Applications (1)

Application Number Title Priority Date Filing Date
GB868601915A Pending GB8601915D0 (en) 1986-01-27 1986-01-27 Pharmaceutical compositions

Country Status (13)

Country Link
US (2) US4753964A (en)
EP (1) EP0234733B1 (en)
JP (1) JPS62185018A (en)
AT (1) ATE69378T1 (en)
AU (1) AU593317B2 (en)
DE (1) DE3774449D1 (en)
ES (1) ES2040242T3 (en)
GB (1) GB8601915D0 (en)
GR (1) GR3003120T3 (en)
HK (1) HK127893A (en)
IE (1) IE59606B1 (en)
SG (1) SG114293G (en)
ZA (1) ZA87560B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120763A (en) * 1986-11-26 1992-06-09 Bar Ilan University Physiologically active and nutritional composition
US5599840A (en) * 1986-11-26 1997-02-04 Bar Ilan University Physiologically active and nutritional composition
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
GB8719988D0 (en) * 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds
ES2040847T3 (en) * 1987-04-27 1996-07-16 Efamol Holdings A PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION CONTAINING A LITHIUM SALT.
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
US4851398A (en) * 1987-09-30 1989-07-25 Elena Avram Bismuth containing pharmaceutical compositions
JP2524217B2 (en) * 1988-04-18 1996-08-14 マルハ株式会社 Brain function improving composition, learning ability enhancing agent, memory enhancing agent, dementia preventive agent or dementia therapeutic agent
AT397201B (en) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr USE OF THE ENZYME COFACTOR NADPH IN THE PRODUCTION OF A MEDICINAL PRODUCT
AT397200B (en) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr USE OF SELENIUM METHIONINE IN THE PRODUCTION OF A MEDICINAL PRODUCT
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
AU620929B2 (en) * 1988-10-27 1992-02-27 Bar-Ilan University Method and compositions for treating alzheimer's disease, related dementias and epilepsy
IL91802A (en) * 1988-10-27 1994-05-30 Univ Bar Ilan Compositions containing linolenic acid derivativesfor treating Alzheimer's disease, related dementias and epilepsy
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
EP1092352A3 (en) * 1991-01-24 2003-08-27 Martek Corporation Microbial oil mixtures and uses thereof
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
WO1994027603A1 (en) * 1993-06-01 1994-12-08 Cortex Pharmaceuticals, Inc. Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
ATE264099T1 (en) * 1993-06-09 2004-04-15 Martek Biosciences Corp METHODS AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
DE59409129D1 (en) * 1993-11-26 2000-03-09 Karla Lehmann USE OF LITHIUM COMPOUNDS FOR TREATING AND PROPHYLAXIS OF ALZHEIMER'S MORBUS
JPH07143862A (en) * 1994-05-06 1995-06-06 Maruha Corp Functional food having cerebral function-improving effect
EP0726073A3 (en) * 1995-02-10 1998-07-08 Eduardo Samuel Bleiweiss Pharmaceutical compositions containing at least one of haloperidol, imipramine or trifluoroperazine
FR2740342B1 (en) * 1995-10-26 1997-12-19 Oreal USE OF LANTHANIDE, MANGANESE, LITHIUM, TIN, ZINC OR YTTRIUM SALT, COBALT, BARIUM, STRONTIUM IN PHARMACEUTICAL COMPOSITIONS
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
KR100657642B1 (en) * 1996-10-11 2006-12-19 스카리스타 리미티드 Oil comprising eicosapentaenoic acid and/or stearidonic acid
JPH11279066A (en) * 1998-03-25 1999-10-12 Mitsubishi Chemical Corp Neurocyte death suppressant containing lithium salt as active ingredient
JP4669095B2 (en) * 1999-07-19 2011-04-13 太陽化学株式会社 Composition for suppressing behavioral problems in pets
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
JP2003048831A (en) 2001-08-02 2003-02-21 Suntory Ltd Composition having preventing and ameliorating action on symptom or disease caused by decrease in brain function
NL1019368C2 (en) 2001-11-14 2003-05-20 Nutricia Nv Preparation for improving receptor performance.
US7378111B2 (en) * 2002-02-20 2008-05-27 The Trustees Of The University Of Pennsylvania Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
ITMI20040069A1 (en) * 2004-01-21 2004-04-21 Tiberio Bruzzese USE OF HIGH CONCENTRATION N-3 FATTY ACID COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
JP4993852B2 (en) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 Composition having a preventive or ameliorating effect on symptoms or diseases accompanied by behavioral abnormalities caused by stress
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
BRPI0613274A2 (en) * 2005-05-23 2009-08-04 Massachusetts Inst Technology pufa-containing compositions and methods of use thereof
JP5967855B2 (en) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 Composition having an activity of reducing daytime activity and / or depressive symptoms
KR20080027384A (en) * 2005-07-08 2008-03-26 마텍 바이오싸이언스스 코포레이션 Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
US20070049565A1 (en) * 2005-08-24 2007-03-01 Neurotech Pharmaceuticals Co., Ltd. Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
US20070298129A1 (en) * 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction
ES2277557B1 (en) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF OXIDATIVE CELL DAMAGE.
BRPI0621248A2 (en) * 2006-01-17 2011-12-06 Majid Fotuhi drug and dosing regimen to prevent or reduce the risk of dementia or onset through administration of specific vitamins and nsaid
AU2007231547B2 (en) * 2006-03-29 2012-07-12 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
JPWO2008081989A1 (en) 2006-12-28 2010-04-30 サントリーホールディングス株式会社 Nerve regeneration agent
US20080181937A1 (en) * 2007-01-29 2008-07-31 Majid Fotuhi Dosage regimen and medicament for guarding memory and brain health and for preventing or reducing risk of onset of dementia by administration of specific vitamins and supplements (memoguard)
US20080234377A1 (en) * 2007-03-23 2008-09-25 Martek Biosciences Corporation Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
WO2008119109A1 (en) 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
KR101397554B1 (en) * 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 Compositions and method for the diagnosis, prevention and treatment of Alzheimer's disease
KR100852962B1 (en) * 2007-11-12 2008-08-20 주식회사 뉴로테크 Manufacturing method of 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and their salts
BRPI1000970A2 (en) * 2010-04-07 2011-11-29 Fundacao Arnaldo Vieira De Carvalho pharmaceutical composition for the treatment of Alzheimer's disease, process for its obtaining and use
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
DE212014000063U1 (en) * 2014-03-24 2015-10-12 China Medical University Use of benzoic acid salt in the manufacture of a composition for the prevention or treatment of dementia or mild cognitive impairment
JP2016023163A (en) * 2014-07-22 2016-02-08 出光興産株式会社 AGENT FOR REDUCING OXIDATIVE STRESS ON NERVE CELLS COMPRISING γ-LINOLENIC ACID
RU2587617C1 (en) * 2014-12-23 2016-06-20 Ольга Алексеевна Громова Method for preventing and treating neurodegenerative pathology and vascular dementia
WO2016191323A1 (en) 2015-05-22 2016-12-01 University Of South Florida Lithium co-crystals for treatment of neuropsychiatric disorders
CN109562089A (en) * 2016-06-13 2019-04-02 心悦生医股份有限公司 Lithium benzoate is used to treat the purposes of central nervous system disease
JPWO2018221244A1 (en) * 2017-05-30 2019-11-21 森永乳業株式会社 Composition for improving brain function
WO2020237203A1 (en) * 2019-05-23 2020-11-26 Indiana University Research And Technology Corporation Methods for objective assessment of memory, early detection of risk for alzheimer's disease, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
US4328243A (en) * 1981-04-07 1982-05-04 Horrobin David F Manic-depressive illnesses
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8319073D0 (en) * 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels

Also Published As

Publication number Publication date
HK127893A (en) 1993-11-26
IE59606B1 (en) 1994-03-09
ZA87560B (en) 1987-09-30
GR3003120T3 (en) 1993-02-17
DE3774449D1 (en) 1991-12-19
EP0234733A1 (en) 1987-09-02
AU593317B2 (en) 1990-02-08
AU6767587A (en) 1987-07-30
US4810497A (en) 1989-03-07
IE870194L (en) 1987-07-27
US4753964A (en) 1988-06-28
ES2040242T3 (en) 1993-10-16
ATE69378T1 (en) 1991-11-15
SG114293G (en) 1994-01-21
JPS62185018A (en) 1987-08-13
EP0234733B1 (en) 1991-11-13

Similar Documents

Publication Publication Date Title
GB8601915D0 (en) Pharmaceutical compositions
DE69125216T2 (en) Aminoalkanesulfonic acid derivatives and pharmaceutical compositions thereof for the prevention or treatment of heart diseases
KR970702291A (en) Anequilin double bond isomer from the acid isomerization of equilin
DE68926115D1 (en) METHOD FOR TREATING ACNE
EP0328634B1 (en) Pharmaceutical compositions for the treatment of psoriasis
KR950000141A (en) Use of L-carnitine O-esters containing aromatic acids for the preparation of pharmaceutical compositions for the treatment of skin diseases
DE2967356D1 (en) Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
DE69207479T2 (en) Use of the esters of acyl-L-carnitine with gamma-hydroxy-butyric acid for the production of pharmaceutical compositions for the treatment of liver diseases
PT79649B (en) Process for preparing pharmaceutical compositions for therapeutical treatment of rheumatic diseases containing oxicam derivatives and 1,2-diacylglycero-3-phosphocholine
DE69315162T2 (en) Use of L-carnitine and acyl-L-carnitine for the treatment of patients suffering from AIDS-related syndromes and of asymptomatic HIV-seropositive patients
GR3006606T3 (en)
EP0383481A3 (en) Anesthetic oral compositions
IT1210874B (en) MAGNESIUM SALT OF KENODEXOXYLIC ACID AND URSODEXOXYLIC ACID, PROCESS FOR LASUAL PREPARATION AND THERAPEUTIC COMPOSITIONS THAT CONTAIN IT AS AN ACTIVE INGREDIENT.
US4156003A (en) Treatment of hypertension with combination of clofibrinic acid or clofibrate with cinnarizine
BE899000A (en) DILTIAZEM COMPOSITIONS FOR PROPHYLAXIS AND TREATMENT OF ARTERIOSCLEROSIS
HK1003942A1 (en) New alkaloid derivatives their use and pharmaceutical formulations containing them
GB1463260A (en) Pharmacologically active acetic acid derivative
ES2058315T3 (en) EFFECTIVE COMPOUNDS AGAINST BRAIN FAILURE.